Phase 4 N=22 Randomized Triple-blind Diagnostic

Comparison of Blood Pressure Medications on Metabolism

Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT00642434 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2023

Primary outcome: Primary: Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline — 0; 0 participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: carvedilol (Drug); metoprolol (Drug)
Age: Adult, Older Adult · 45+ yrs
Sex: All
Sponsor: University of New Mexico
Primary completion: Jun 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline	0; 0	—

Summary

The purpose of this study is to determine if there are differences, (benefits) between carvedilol and metoprolol in the treatment of HTN in patients with type 2 diabetes. Specifically we will be looking at differences in blood pressure and blood sugar control, endothelial function, inflammation, oxidative stress and coagulation. Subjects will be randomized to one of the two beta-blockers and followed for 5 months. Each subject will undergo 4 inpatient studies where an oral glucose tolerance test will be done, Inflammatory and oxidative stress markers will be measured. Endothelial function will be measured using brachial artery ultrasound and laser skin Doppler

Eligibility Criteria

Inclusion Criteria

not enrolling

Exclusion Criteria

not enrolling

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00642434). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.